INSMED (INSM) revenue: $606M
INSMED reported $606M of revenue for the year ended Dec 31, 2025, up 66.7% from $364M a year earlier.
From INSMED's filings with the SEC · Read the filing · INSM stock page
INSMED revenue by year
#1,887 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $606M | +67% |
| Dec 31, 2024 | $364M | +19% |
| Dec 31, 2023 | $305M | +24% |
| Dec 31, 2022 | $245M | +30% |
| Dec 31, 2021 | $188M | – |
Revenue of similar companies
Companies in the same industry as INSMED, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Kiniksa Pharmaceuticals International | $678M | Dec 31, 2025 |
| Ultragenyx Pharmaceutical | $673M | Dec 31, 2025 |
| Axsome Therapeutics | $638M | Dec 31, 2025 |
| TG Therapeutics | $616M | Dec 31, 2025 |
| Opko Health | $607M | Dec 31, 2025 |
| INSMED | $606M | Dec 31, 2025 |
| HUTCHMED (China) | $549M | Dec 31, 2025 |
Questions and answers
What is INSMED's revenue?
INSMED reported $606M of revenue for the year ended Dec 31, 2025, up 66.7% from $364M a year earlier.
Numbers as reported in INSMED's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology